Benefit of Diverse Surgical Approach on Short-term Outcomes of MEN1-related Hyperparathyroidism
Authors
Affiliations
Surgical excision is the preferred treatment for multiple endocrine neoplasia type 1 (MEN1)-related primary hyperparathyroidism (PHPT), although controversy regarding the surgical strategy exists. We retrospectively investigated the short-term outcomes of PHPT by various surgical extents. Thirty-three patients who underwent parathyroidectomy due to MEN1-related PHPT at Yonsei Severance Hospital between 2005 and 2018 were included (age [mean ± SD], 43.4 ± 14.1 [range, 23-81] years). Total parathyroidectomy with auto-transplantation to the forearm (TPX) was the most common surgical method (17/33), followed by less-than-subtotal parathyroidectomy (LPX; 12/33) and subtotal parathyroidectomy (SPX; 4/33). There was no postoperative persistent hyperparathyroidism. Recurrence was high in the LPX group without significance (1 in TPX, 2 in SPX, and 3 in LPX, p = 0.076). Permanent and transient hypoparathyroidism were more common in TPX (n = 6/17, 35.3%, p = 0.031; n = 4/17, 23.5%, p = 0.154, respectively). Parathyroid venous sampling (PVS) was introduced in 2013 for preoperative localisation of hyperparathyroidism at our hospital; nine among 19 patients operated on after 2013 underwent pre-parathyroidectomy PVS, with various surgical extents, and no permanent hypoparathyroidism (p = 0.033) or post-LPX recurrence was observed. Although TPX with auto-transplantation is the standard surgery for MEN1-related PHPT, surgical extent individualisation is necessary, given the postoperative hypoparathyroidism rate of TPX and feasibility of PVS.
Boucher A, Delabie J, Lussey-Lepoutre C, Haissaguerre M, Ouvrard E, Lavinia V Eur J Nucl Med Mol Imaging. 2023; 51(5):1349-1360.
PMID: 38057652 DOI: 10.1007/s00259-023-06537-1.
Liu Z, Zhao Y, Han X, Hu X, Zhang Y, Xu L Front Endocrinol (Lausanne). 2023; 14:1175377.
PMID: 37795364 PMC: 10546301. DOI: 10.3389/fendo.2023.1175377.
Ruggeri R, Benevento E, De Cicco F, Grossrubatscher E, Hasballa I, Tarsitano M Endocrine. 2023; 82(3):480-490.
PMID: 37632635 DOI: 10.1007/s12020-023-03497-2.
Tan J, Zeng L, Wang Y, Liu G, Huang L, Chen D Front Genet. 2022; 13:845081.
PMID: 35957697 PMC: 9358689. DOI: 10.3389/fgene.2022.845081.
Bouriez D, Gronnier C, Haissaguerre M, Tabarin A, Najah H World J Surg. 2022; 46(11):2666-2675.
PMID: 35767091 DOI: 10.1007/s00268-022-06633-7.